Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
23RD IN
FECTIO
N AND
SEPS
IS SY
MPOSIU
M ANTIBIOTIC THERAPY COURSE09-10 MARCH | HOSPITAL LUSÍADAS | PORTO
CONGRESS COURSES:
07 - 09
MAR
CH 20
18 | S
HERATON PORTOANTIBIOTIC STEWARDSHIP- LESSONS LEARNED- IMPLEMENTING SUCCESSFUL PROGRAMS- ENGAGING KEY STAKEHOLDERSCHALLENGING INFECTIONS- SEVERE INFECTIONS BY XDR BUGS- IMMUNOCOMPROMISED HOSTS- THE ROLE OF THE NEWER BETA-LACTAMSSEPSIS: THE WAY FORWARD- IMPACT OF THE REVISED DEFINITIONS- BIG DATA ANALYSIS- NOVEL THERAPEUTIC TARGETS
MAIN TOPICS:
1 2
09h00-10h30 Antimicrobial Stewardship – 2018Chairmen: António Sarmento | Dulce Pascoalinho
- Implementing an effective AMS program - Strategies to improve the contribution of the micro lab- Engaging key stakeholders
Carlos Alves
Vittorio Sambri
Massimo Sartelli
10h30-11h00 Surviving in an endemic situation - George DimopoulosChairman: Álvaro Ayres Pereira
11h00-11h20 Coffee-Break11h20-11h40 Opening Session11h40-13h10 Emerging Threats
Chairmen: Manuela Ribeiro | TBA
- Candida Auris- Invasive aspergillosis in critically ill patients - Are we neglecting MRSA?
José Manuel Pereira
Stijn Blot
José Melo Cristino
13h10-13h40 Accelerate Satellite Symposium: Clinical value of faster antimicrobial susceptibility testing - Tiziana Di Martino
13h40-15h00 Lunch15h00-15h30 Assessment of MDR risk - focus on ESBL - Nuno Pereira
Chairman: J. Saraiva da Cunha
15h30-17h00 The way forwardChairmen: José Artur Paiva | José Neves
- The National Program of Infection Control and Antimicrobial Resistance: Opportunities and Challenges - Optimizing the yield of blood cultures- Money makes the world go around: economic impact of AMS
Isabel Neves
Vittorio Sambri
Carlos Palos
17h00 Poster Presentation17h00-17h30 Coffee-break17h30-18h00 A research agenda on infection in the ICU - Stijn Blot
Chairman: Paulo Mergulhão
09h00-10h30 Infections in transplant recipientsChairmen: Filomena Faria | Júlio Nóbrega
- An overview of infections in transplant recipients- Lung transplant- HSCT
Gerardo Oliveira
Carla Damas
Ricardo Pinto
10h30-11h00 Severe PsA infection in 2018 - David P. NicolauChairman: Paulo Mergulhão
11h00 Poster Presentation11h00-11h30 Coffee-break11h30-13h00 Carbapenem-resistant enterobactereacea
Chairmen: João João Mendes/ TBA
- The conundrum of telling colonisation from infection- Treatment of bacteraemia- Once a carrier, always a carrier?
Lurdes Santos
George Dimopoulos
Cláudia Nazareth
13h00-13h30 Astellas Satellite Symposium: Invasive Candidiasis- António Messias
13h30-15h00 Lunch15h00-16h30 TDM
Chairmen: João Pedro Baptista | Rui Veiga
- Pk/Pd targeted therapy: what are we missing?- What do we really know about MIC targets?- Aminoglicosides - what has changed?
David P. Nicolau
Jan de Waele
João Gonçalves Pereira
16h30-17h00 Source control in abdominal sepsis: what do we really know? - Massimo SartelliChairman: Irene Aragão
17h00 Poster Presentation17h00-17h30 Coffee-break17h30-18h30 The pipeline
Chairmen: João Gonçalves Pereira | Edgar Botelho Moniz
- Advantages and pitfalls of the new β-lactams- Novel antifungal agents- Innovative views to combat infection
Márcio Borges-Sá
Jan de Waele
George Dimopoulos
3 4
09h00-09h30 Assessing prognosis in AKI - Sérgio GaiãoChairman: TBA
09h30-10h00 Optimal fluid management in sepsis - Miguel TavaresChairman: TBA
10h00 Poster Presentation10h00-10h30 Coffee-Break10h30-12h00 Sepsis
Chairmen: Paula Coutinho | Rui Moreno
- New Sepsis definitions: advantages and pitfalls- Can big data change the way we practice medicine?- SSC 2016 recommendations and the National Guidelines
Paulo Mergulhão
Márcio Borges-Sá
Júlio Nóbrega
12h00-12h30 Sepsis in 2018: Lessons learned and future perspectives - José Artur PaivaChairman: Jorge Pimentel
12h30-13h00 Closing conference: The Infection and Sepsis Group 2018-9
5 6
7 8
C/T S (%) C/T R (%)
Enterobacterales (77) 39 61
E. coli ESBL + (13) 77 23
E. coli ESBL – (4) 100 -
K. pneumonia ESBL + (28) 28,6 71,4
K. pneumonia ESBL - (14) 21,4 78,6
Other Enterobacterales (18) 27,8 72,2
P. aeruginosa (12) 83,3 16,7
9 10
Antimicrobiano Resistência (%)
Imipenem 90,6
Meropenem 90,3
Gentamicina 56,1
Amicanina 47,2
Ceftazidima 38,9
Piperacilina-tazobactam 90,9
Ciprofloxacina 85,9
Colistina 0
Ceftolozano-tazobactam 14,6
11 12
13 14
15 16
17 18
19 20
21
MAJOR SPONSORS
B|BRAUN
SPONSORS
Grupo de
Infecção e Sepsis